CJ
CJMB.US Callan JMB Inc. Common Stock
- Market cap
- USD 2.86M
- P/E
- -
- P/B
- 3.81x
- ROE
- -1,304.4%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is CJMB.US undervalued?
Graham numberThe Graham number of Callan JMB Inc. Common Stock cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Callan JMB Inc. Common Stock fundamental analysis
No fundamental analysis for Callan JMB Inc. Common Stock yet.
Callan JMB Inc. Common Stock stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Callan JMB Inc. Common Stock
Callan JMB Inc., through its subsidiary, Coldchain Technology Services, LLC provides thermal management logistics solutions to the life sciences industry in United States. It offers logistics solutions and services utilized for frozen shipping in the life sciences industry, including personalized medicine, cell therapies, stem cells, cell lines, vaccines, diagnostic materials, semen, eggs, embryos, cord blood, organs, biopharmaceuticals, infectious substances, and other comm…
Full company profileCallan JMB Inc. Common Stock financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Callan JMB Inc. Common Stock annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 22.8M | 13.2M | 6.56M | 5.72M | 4.96M |
| Gross Profit | 9.45M | 5.65M | 2.56M | 2.10M | 2.37M |
| Operating Income | 6.30M | 2.20M | -2.27M | -6.49M | -6.10M |
| EBITDA | 6.37M | 2.31M | -2.12M | -7.81M | -8.73M |
| Net Income | 6.22M | 2.18M | -2.29M | -7.97M | -8.89M |
| EPS | 1.24 | 0.44 | -0.38 | -1.82 | -1.58 |
| Balance Sheet | |||||
| Total Assets | 15.3M | 9.71M | 5.08M | 5.78M | 4.45M |
| Total Liabilities | 1.24M | 910K | 1.91M | 3.45M | 3.77M |
| Shareholders' Equity | 14.0M | 8.80M | 3.17M | 2.33M | 682K |
| Cash & Short-term Investments | 6.19M | 5.16M | 2.10M | 2.13M | 860K |
| Total Debt | 411K | 400K | 907K | 2.00M | 2.14M |
| Cash Flow | |||||
| Operating Cash Flow | 9.36M | 7.00M | 540K | -4.55M | -4.15M |
| Capital Expenditure | 422K | 490K | 46.2K | 617K | 139K |
| Free Cash Flow | 8.94M | 6.51M | 494K | -5.16M | -4.29M |
| Ratios | |||||
| ROE | 44.4% | 24.8% | -72.3% | -342.2% | -1,304.4% |
| ROA | 40.8% | 22.5% | -45.1% | -137.9% | -199.8% |
| Net Profit Margin | 27.3% | 16.5% | -34.9% | -139.2% | -179.1% |
| Debt to Equity | 0.03x | 0.05x | 0.29x | 0.86x | 3.14x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Callan JMB Inc. Common Stock dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | USD 3.33M | 0.56 | - |
| 2023 | USD 7.40M | 1.48 | 339.1% |
| 2022 | USD 4.45M | 0.89 | 71.5% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Callan JMB Inc. Common Stock
- Insiders 56.45%
- Institutions 14.15%
- Public & others 29.41%
- Shares outstanding 7.01M
- Free float 3.09M
Top funds holding CJMB.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Nasdaq Composite Index | 178K | 2.54% | 0.00% | Aug 2026 |
| Fidelity Extended Market Index | 23.8K | 0.34% | -0.21% | Sep 2026 |
| Fidelity Series Total Market Index | 2.07K | 0.03% | 0.00% | Sep 2026 |
Top institutions holding CJMB.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Creative Planning Inc | 256K | 3.84% | 0.00% | Jun 2026 |
| Bard Associates Inc | 229K | 3.44% | -6.61% | Jun 2026 |
| Citadel Advisors Llc | 32.1K | 0.48% | 0.00% | Jun 2026 |
| Axxcess Wealth Management, LLC | 25.0K | 0.38% | 0.00% | Jun 2026 |
| Geode Capital Management, LLC | 15.7K | 0.24% | -31.77% | Jun 2026 |
| Financial Plan, INC. | 13.5K | 0.20% | 0.00% | Jun 2026 |
| Citigroup Inc | 13.4K | 0.20% | 0.00% | Jun 2026 |
| HighTower Advisors, LLC | 12.5K | 0.19% | 0.00% | Jun 2026 |
| XTX Topco Ltd | 11.3K | 0.17% | 0.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 6.66K | 0.10% | 0.00% | Jun 2026 |
| UBS Group AG | 5.64K | 0.08% | +245.35% | Jun 2026 |
| Qsemble Capital Management, LP | 1.56K | 0.02% | -67.67% | Jun 2026 |
| Tower Research Capital LLC | 434.00 | 0.01% | -79.03% | Jun 2026 |
| Caitong International Asset Management Co., Limited. | 1.00 | 0.00% | -50.00% | Jun 2026 |
| Barclays PLC | 1.00 | 0.00% | 0.00% | Jun 2026 |
| Jane Street Group LLC | 0.00 | 0.00% | -100.00% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 0.00 | 0.00% | -100.00% | Jun 2026 |
| HRT FINANCIAL LLC | 0.00 | 0.00% | -100.00% | Jun 2026 |
Callan JMB Inc. Common Stock company profile
- Company name
- Callan JMB Inc. Common Stock
- Ticker
- CJMB.US
- Exchange
- USA Stocks
- Listed since
- Feb 5, 2025
- Sector
- Industrials
- Industry
- Air Freight & Logistics
- Employees
- 18
- Fiscal year end
- December
- Address
- 244 Flightline Drive, Spring Branch, TX, United States, 78070-6241
- Phone
- 830 438 0395
- Website
- callanjmb.com
About Callan JMB Inc. Common Stock
Callan JMB Inc., through its subsidiary, Coldchain Technology Services, LLC provides thermal management logistics solutions to the life sciences industry in United States. It offers logistics solutions and services utilized for frozen shipping in the life sciences industry, including personalized medicine, cell therapies, stem cells, cell lines, vaccines, diagnostic materials, semen, eggs, embryos, cord blood, organs, biopharmaceuticals, infectious substances, and other commodities. The company also provides emergency preparedness services, which includes managing their building sites, medical stockpiles of equipment, and supplies and responding to state or local emergencies; specialty temperature-regulating packaging; technical services; and advanced monitoring sentry technology. In addition, the company engages in oil and gas development business. Callan JMB Inc. has strategic partnership with Alabama State University to advance the United States pharmaceutical manufacturing and supply chain resilience. The company was founded in 2006 and is headquartered in Spring Branch, Texas.
Callan JMB Inc. Common Stock management
6- Mr. Wayne WilliamsFounder, CEO, President & Chairman · born 1964
- Mr. Christopher ShieldsInterim CFO & Senior VP of Governmental Affairs and COO · born 1969
- Dr. David J. Croyle M.D.Chief Medical Officer · born 1959
- Mr. Wiliam McBrideChief Information Officer
- Mr. Andrew WeigmanSenior Vice President of Land & Acquisitions
- Mr. Michael L. RegerPresident of Callan Power & Director · born 1976